Skip to Main Content Menu Search Site

FeCILL: Reimagining How We Treat the Sickest Patients

Previous Next

Opportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute and Massachusetts General Hospital are developing a new delivery method for systemic antifungals that could help reduce negative side effects and better target the infection.

Credit: Wyss Institute at Harvard University

Close menu